16.44 USD
▼-0.87-5.03%
盘后 16.12 0.00%
2026-09-15
市值
$993.17M
市盈率
—
EPS
-1.64
股息率
—
52 周区间
12.12 – 35.34
成交量
1.01M
Beta
2.52
目标价
36.24
52W 低 12.1252W 高 35.34
价格走势
公司简介
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008...